Rx Price Watch report: retail prices for widely used brand name drugs increase considerably prior to generic competition
- Series Title(s):
- Insight on the issues (AARP Public Policy Institute)
- Contributor(s):
- Schondelmeyer, Stephen. Purvis, Leigh. AARP (Organization) Public Policy Institute (AARP (Organization))
- Publication:
- Washington, D.C. : AARP Public Policy Institute, c2011
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Drug Costs -- trends Drug Therapy -- statistics & numerical data Economic Competition Pharmaceutical Preparations -- economics Drug Approval Drug Costs -- statistics & numerical data Forecasting Medicare Part D -- economics Patents as Topic Humans United States
- Genre(s):
- Technical Report
- Abstract:
- AARP's Public Policy Institute has been tracking price changes for widely used prescription drug products since 2004, with quarterly and annual results reaching back as far as 2000. Previous studies have used a market basket of drugs based on actual drug utilization in a Medicare Part D plan during calendar year 2006. Our reports on price changes have included the overall price change across all types of drug products in our market basket as well as specific analysis of the retail price changes found for each of the drug subgroups--brand name, generic, and specialty drugs. This report focuses on changes in the retail prices for brand name drug products widely used by Medicare beneficiaries. In particular, the report examines changes in the retail prices of brand name drugs both before and after patent expiration to see how the change in patent status affects retail prices.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101564950 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101564950